证券代码：002432 证券简称：九安医疗 公告编号：2025-019 天津九安医疗电子股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日召 开了第六届董事会第二十次会议，会议决定于 2025 年 4 月 21 日召开公司 2025 年第一次临时股东大会，本次股东大会采用现场投票及网络投票相结合的方式进 行。根据《公司章程》的规定，现将召开本次股东大会的有关事项公告如下： 一、召开会议基本情况 1、股东大会届次：2025 年第一次临时股东大会 7、出席对象 （1）在股权登记日持有公司股份的普通股股东或其代理人； 2、会议召集人：公司董事会 3、公司第六届董事会第二十次会议审议通过了《关于召开 2025 年第一次临 时股东大会的议案》，本次股东大会会议召开符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 4、会议召开的日期和时间 （1）现场会议时间：2025 年 4 月 21 日下午 14:0 ...

天津九安医疗电子股份有限公司（以下简称"公司"或"本公司"）于2025年3 月31日以传真和邮件方式发出召开第六届董事会第二十次会议的通知，会议于 2025年4月3日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司 董事长刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、 公司高级管理人员列席了会议，符合《公司法》及《公司章程》的规定。会议以 投票表决方式通过如下议案： 一、以6票同意、0票反对、0票弃权的表决结果，审议通过了《关于部分募 集资金投资项目延期、结项及节余募集资金使用的议案》 证券代码：002432 证券简称：九安医疗 公告编号：2025-016 天津九安医疗电子股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 本议案涉及延期事项在董事会审议权限范围内，节余募集资金使用事项尚需 提交股东大会审议。 具体内容详见公司于 2025 年 4 月 4 日 在 《 证 券 时 报 》 及 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《关于部分募集资金 ...

太平洋证券股份有限公司 关于天津九安医疗电子股份有限公司 部分募集资金投资项目延期、结项 及节余募集资金使用的核查意见 天津九安医疗电子股份有限公司（以下简称"九安医疗"、"公司"）于 2025 年 4 月 3 日召开的第六届董事会第二十次会议、第六届监事会第十五次会议，审 议通过了《关于部分募集资金投资项目延期、结项及节余募集资金使用的议案》， 鉴于公司募集资金项目"糖尿病照护服务及相关产品研发项目"之子项目"共同照 护中心扩展及系统研发升级项目"已经完成结项，为提高募集资金使用效率，进 一步满足新增人才的扩容及办公需要和智能家用医疗器械的研发需求，以及推动 持续血糖监测系统（CGMS）研发项目的加速实施，公司拟将剩余募集资金用于 "研发办公总部大楼建设及原厂区升级改造项目"和"糖尿病照护服务及相关产品 研发项目"之子项目"持续血糖监测系统（CGMS）研发项目"。 太平洋证券股份有限公司（以下简称"太平洋证券"、"保荐机构"）作为九安 医疗 2020 年非公开发行股票项目的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《深圳证券交易所股 ...

Core Insights - Liaocheng Jiukao Electronic Technology Co., Ltd. has been established with a registered capital of 500,000 yuan, and its legal representative is Li Kang [1] - The company’s business scope includes a wide range of services such as technology services, electronic equipment sales, information technology consulting, and various types of product sales [1] - Jiukao Electronic is fully owned by Jiuan Medical, indicating a strategic alignment with the parent company’s interests in the electronic and medical sectors [1] Business Scope - The company offers technology services, development, consulting, and promotion, indicating a focus on innovation and technical support [1] - It engages in the sale of electronic components, communication equipment, and various consumer goods, showcasing a diverse product portfolio [1] - The inclusion of services like software development, information system integration, and IoT technology services highlights the company's commitment to modern technological solutions [1] Ownership Structure - Jiukao Electronic is wholly owned by Jiuan Medical, which may provide financial stability and strategic direction [1]

Core Points - The Shanghai Composite Index opened lower and fluctuated, while the CSI All Index for Healthcare Equipment and Services decreased by 0.16%, closing at 14,029.54 points with a trading volume of 15.519 billion yuan [1] - Over the past month, the CSI All Index for Healthcare Equipment and Services has increased by 0.23%, and over the past three months, it has risen by 2.65%, with a year-to-date increase of 2.65% [1] - The index reflects the overall performance of listed companies in the healthcare sector, selected from the CSI All Index, with a base date of December 31, 2004, set at 1,000.0 points [1] Index Composition - The top ten weighted companies in the CSI All Index for Healthcare Equipment and Services are: Mindray Medical (9.28%), Aier Eye Hospital (8.07%), United Imaging (6.7%), Aimeike (3.56%), Huatai Medical (3.16%), New Industry (3.09%), Yuyue Medical (2.83%), Meinian Onehealth (2.33%), Jiuan Medical (2.16%), and Shandong Pharmaceutical Glass (2.05%) [1] - The market share of the index's holdings is 61.07% from the Shenzhen Stock Exchange and 38.93% from the Shanghai Stock Exchange [1] - The index's holdings are entirely composed of the pharmaceutical and healthcare sector, with a 100.00% allocation [1] Index Adjustment and Fund Tracking - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample changes, typically remaining fixed until the next scheduled adjustment, with provisions for temporary adjustments in special circumstances [2] - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, specifically designed to follow the CSI All Index for Healthcare Equipment and Services [2]

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Core Viewpoint - The company has approved a share repurchase plan with a total funding amount between 250 million RMB and 500 million RMB, aiming to enhance shareholder value and stabilize stock prices [1]. Summary by Sections Share Repurchase Plan - The company will use its own funds and special loan funds for the repurchase, with a maximum repurchase price set at 50 RMB per share [1]. - The total number of shares repurchased will be determined at the end of the repurchase period [1]. Progress of Share Repurchase - As of March 31, 2025, the company has repurchased a total of 1,193,900 shares, accounting for 0.25% of the total share capital [1]. - The highest transaction price was 42.17 RMB per share, while the lowest was 41.64 RMB per share, with a total expenditure of approximately 49.995 million RMB (excluding transaction fees) [1]. Compliance with Regulations - The company has adhered to relevant regulations regarding the timing, quantity, and pricing of the share repurchase [2][3]. - The repurchase does not occur during periods that could significantly impact the stock price or during other restricted periods as defined by regulatory authorities [2].

证券代码：002432 证券简称：九安医疗 公告编号：2025-015 天津九安医疗电子股份有限公司 关于回购公司股份的进展公告 1、公司未在下列期间内回购公司股票： （1）自可能对公司股票交易价格产生重大影响的重大事项发生之日或者在 决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号—回购股份》等相关规定，公司在回购期间应当在每个月的前3个交易日内公 告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购股份的具体情况 截至2025年3月31日，公司通过股份回购专用证券账户以集中竞价方式累计 回购公司股份数1,193,900股，占公司总股本的0.25%，最高成交价为42.17元/股， 最低成交价为41.64元/股，支付的总金额为人民币49,995,031.30元（不含交易费 用）。本次回购符合相关法律法规的要求，符合既定的回购股份方案。 二、其他说明 公司回购股份的时间、数量、价格及集中竞价交易的委托时间段均符合《深 圳证券交易所上市公司自律监管指引第9号—回购股份》及公司回购股份方案的 ...

Core Viewpoint - Recent adjustments by prominent fund managers in sectors such as healthcare, new energy, and AI computing have been revealed through the latest holdings announcements from listed companies [1]. Group 1: Adjustments by Fund Managers - Fund manager Ge Lan reduced holdings in Jiuan Medical, decreasing from 577 million shares to 423 million shares, a reduction of 154 million shares [4][5]. - Fund managers He Shuai and Shen Nan increased their positions in Weili Transmission, with slight increases in holdings across multiple funds [6][7]. - Fund manager Han Chuang significantly increased holdings in Woge Optoelectronics from 98 million shares to 253 million shares, an increase of 155 million shares [10][11]. Group 2: Company Insights - Jiuan Medical is a significant player in the global in vitro diagnostics and home healthcare products sector, with a comprehensive range of personal health wearable devices [4][5]. - Weili Transmission specializes in high-end planetary gear reducers for wind power applications, leveraging its experience and technology to meet the demands of downstream manufacturers [6][8]. - Woge Optoelectronics focuses on glass precision processing, providing various services including thinning and anti-static ITO coating, and is actively developing projects in the glass-based TGV substrate sector [10][11].